Summary: Rett syndrome is usually treated as a single disorder caused by defects in the MECP2 gene. New research using patient-derived 3D human brain organoids shows that different MECP2 mutations produce fundamentally different cellular and network-level changes. These differences require distinct, targeted interventions rather than a one-size-fits-all treatment.
Researchers grew cortical “minibrains” from cells donated by Rett syndrome patients and compared organoids carrying two clinically important MECP2 mutations: the more common missense mutation R306C and the rarer, truncating mutation V247X. Their results reveal mutation-specific alterations in structure, gene expression, neuronal activity, and connectivity—and identify pharmacological strategies tailored to each mutation’s unique deficits.
Key Findings
- Network divergence: Small-world propensity (SWP), a measure of efficient information processing in brain networks, was reduced in R306C organoids but increased in V247X organoids—indicating opposite directions of network disruption.
- Distinct cellular problems: V247X organoids displayed abnormal astrocytes and a marked loss of GABA receptor expression, which weakened inhibitory signaling. R306C organoids, by contrast, overexpressed HDAC2, a gene that represses expression of other genes.
- Targeted treatments: An HDAC2 inhibitor normalized activity and network metrics in R306C organoids, while the GABA agonist baclofen restored network properties in V247X organoids.
Source: Picower Institute at MIT
Although Rett syndrome is caused by mutations in a single gene, MECP2, this study from the Picower Institute for Learning and Memory at MIT demonstrates that individual mutations can produce markedly different outcomes at cellular and network levels. Correcting those outcomes required mutation-specific interventions, supporting the move toward precision medicine for single-gene neurodevelopmental disorders.
“Individual mutations matter,” said Mriganka Sur, senior author of the study published in Nature Communications and Newton Professor in The Picower Institute and the Department of Brain and Cognitive Sciences. “This work shows a path to personalized treatment even for conditions tied to a single gene.”
The team derived cortical organoids from induced pluripotent stem cells made from patient skin or blood samples. These organoids recreate aspects of early human cortical development and permit detailed measurement of anatomy, gene expression, and live neural activity.
Distinct effects
MECP2 has more than 800 known pathogenic variants, but a small subset accounts for most clinical cases. The researchers selected R306C, a missense mutation that changes a single base pair and represents about 7–8% of Rett cases, and V247X, a rare truncating mutation that deletes a base pair and produces an incomplete protein with more severe consequences.
After three months in culture, organoids with V247X showed several structural abnormalities—including increased size and altered layer thickness—whereas R306C organoids resembled controls more closely. Both mutant types showed reduced axon projection development compared to isogenic controls.
Using three-photon microscopy and calcium imaging to monitor activity throughout ~1 mm-thick organoids, the team found that both mutations reduced spike rates and neuron synchrony. Yet measures of network topology diverged: SWP decreased in R306C organoids but increased in V247X organoids, indicating that network organization was altered in opposite ways by each mutation.
To validate relevance to patients, the researchers collaborated with Charles Nelson’s group at Boston Children’s Hospital and examined EEG recordings from children with comparable mutations. Although the clinical sample was small, EEG metrics showed changes consistent with the organoid findings.
Treatment tests
Single-cell RNA sequencing revealed hundreds of gene expression differences in each mutant organoid type. R306C organoids showed elevated expression of HDAC2, a chromatin regulator that suppresses transcription. V247X organoids had reduced expression of GABA(A) receptor subunits and signs of astrocyte dysfunction.
These molecular insights guided targeted pharmacology. An HDAC2 inhibitor rescued neuronal activity levels and restored SWP in R306C organoids. In V247X organoids, the GABA agonist baclofen recovered SWP to control values. Both compounds are already characterized in other clinical contexts, which could facilitate repurposing and faster translation to trials focused on specific genetic subtypes.
Building on this platform, the team plans to examine additional MECP2 mutations and compare them against a standardized control organoid to map mutation-specific vulnerabilities and treatment responses systematically.
Authors include Tatsuya Osaki (lead author), Chloe Delepine, Yuma Osako, Devorah Kranz, April Levin, Charles Nelson, Michela Fagiolini, and Mriganka Sur.
Funding: Supported by the National Institutes of Health, a MURI grant, The Freedom Together Foundation, and the Simons Foundation.
Key Questions Answered:
A: Different MECP2 mutations disrupt different cellular programs and network architectures. One mutation may silence critical genes; another may impair inhibitory signaling or astrocyte support. Effective therapy must address the specific molecular and network deficits produced by each mutation.
A: Minibrains are organoids—small, 3D assemblies of human cortical tissue grown from a patient’s cells. They recreate patient-specific aspects of brain development in vitro, allowing researchers to observe mutation effects and test drugs without exposing patients to risk.
A: This work is a major advance toward personalized therapies. While not an immediate cure, identifying mutation-specific targets and repurposing existing drugs could accelerate clinical trial pathways tailored to genetic subtypes of Rett syndrome.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The journal paper was reviewed in full.
- Additional context was added by staff.
About this neuroscience research news
Author: David Orenstein
Source: Picower Institute at MIT
Contact: David Orenstein – Picower Institute at MIT
Image: The image is credited to Neuroscience News
Original Research: Open access. Title: “Early differential impact of MeCP2 mutations on functional networks in Rett syndrome patient-derived human cortical organoids” by Tatsuya Osaki, Chloe Delepine, Yuma Osako, Devorah Kranz, April Levin, Charles Nelson, Michela Fagiolini & Mriganka Sur. DOI: 10.1038/s41467-026-71458-0
Abstract
Early differential impact of MeCP2 mutations on functional networks in Rett syndrome patient-derived human cortical organoids
Human cortical organoids derived from induced pluripotent stem cells can model early developmental events and reveal disruptions associated with neurodevelopmental disorders. Mutations in the X-linked MECP2 gene cause Rett syndrome, with clinical severity influenced by mutation type and location. This study compared two MECP2 mutations—a missense R306C and a truncating V247X—using calcium imaging and three-photon microscopy to assess neuronal activity and network organization. Both mutation types produced abnormal neuronal activity and altered graph-theoretic network properties, with V247X causing more severe functional connectivity deficits than R306C. EEG recordings from patients with comparable mutations showed parallel changes. Single-cell transcriptomics revealed HDAC2-associated repression in R306C organoids and reduced GABA(A) receptor expression in V247X organoids. These findings identify mutation-specific vulnerabilities and point to targeted therapeutic strategies.